MGMT promoter methylation as a prognostic biomarker for benefit front dose-intensified temozolomide rechallenge in progressive glioblastoma; First results from the randomized phase II DIRECTOR trial

Tabatabal, Ghazaleh and Wick, Wolfgang and Steinbach, Joachim Peter and Wick, Antje and Schnell, Oliver and Hau, Peter and Herrlinger, Ulrich and Sabel, Michael and Wlrsching, Hans-Georg and Ketter, Ralf and Baehr, Oliver and Platten, Michael and Tonn, Joerg and Huesing, Johannes and Reifenberger, Guido and Weller, Michael (2014) MGMT promoter methylation as a prognostic biomarker for benefit front dose-intensified temozolomide rechallenge in progressive glioblastoma; First results from the randomized phase II DIRECTOR trial. JOURNAL OF CLINICAL ONCOLOGY, 32 (15supp): 2015. ISSN 0732-183X, 1527-7755

Full text not available from this repository.
Item Type: Article
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Neurologie
Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT)
Depositing User: Petra Gürster
Date Deposited: 24 Jul 2020 09:00
Last Modified: 24 Jul 2020 09:00
URI: https://pred.uni-regensburg.de/id/eprint/10173

Actions (login required)

View Item View Item